Incidence of community acquired lower respiratory tract disease in Bristol, UK following the emergence of SARS-CoV-2: a prospective cohort study 2020-2024

Competing Interest Statement

CH is Principal Investigator of the AvonCAP study which is a university-guided collaboration between the University of Bristol (sponsor) and Pfizer (funder) and has previously received support from the NIHR in an Academic Clinical Fellowship. JO is a Co-Investigator on the AvonCAP Study. LD is further supported by UKRI through the JUNIPER consortium (grant number MR/V038613/1), MRC (grant number MC/PC/19067), EPSRC (EP/V051555/1 and The Alan Turing Institute, grant EP/N510129/1). AF is a member of the UK Joint Committee on Vaccination and Immunization (JCVI). In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation and is an investigator in recent trials of COVID19 vaccines including ChAdOx1nCOV-19, Janssen and Valneva vaccines. The AvonCAP is conducted as a university-guided collaboration between the University of Bristol (sponsor) and Pfizer (funder). EB, JS, ML, JC, AV, GE, and BG are employees of Pfizer and may own Pfizer stock. The other authors have no relevant conflicts of interest to declare.

Clinical Protocols

https://www.isrctn.com/ISRCTN17354061

Funding Statement

This study was conducted as a university-guided collaboration between the University of Bristol (sponsor) and Pfizer (funder). The study funder had no role in data collection, but collaborated in study design, and manuscript preparation. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Health Research Authority Research Ethics Committee East of England, Essex, reference 20/EE/0157, ISRCTN:17354061. Informed consent was obtained from cognisant patients, and declarations for participation from consultees for individuals lacking capacity. If it was not practical to approach individuals for consent, data were included using approval from the Clinical Advisory Group under Section 251 of the 2006 NHS Act.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes